The first clinical trial in the US of a therapy based on the CRISPR–Cas9 gene editing
system is more likely to be conducted by an academic group than by one of the biotech
firms most closely associated with the commercial development of the technology.
Nat Biotechnol. 2017 Jan 10;35(1):3-5.
Para acessar a publicação na íntegra clique aqui